Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck JV Ties Up With MEND To Focus On First Heat-stable Rotavirus Vaccine For Developing Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Hilleman Laboratories - the nonprofit joint venture between Merck & Co. and Wellcome Trust to develop affordable vaccines for low-income countries - has set its sights on developing a heat-stable form of rotavirus vaccine as its first project

You may also be interested in...



Hilleman Labs Makeover Rides On New Technology For Heat-stable Rotavirus Vaccines

The vaccines research JV between Merck and Wellcome Trust has undergone major changes in its operations. The new plan is dramatically different from the one envisioned at the launch of the JV and narrows down on fewer disease areas with a predominant presence in enteric illnesses.

With Closer Eye On Indian Units, U.S. FDA Names Altaf Lal As New Country Director

Four years after it established its first India base, U.S. FDA has effected a leadership change. The new chief is expected to play a double role as both guide and vigilant examiner.

MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)

Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.

Related Content

UsernamePublicRestriction

Register

SC076259

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel